Login
Subscribe
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Antiviral Pill Lowers Risks of COVID-19 Hospitalization, Death
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
Merck reports that its antiviral molnupiravir was effective against early stages of COVID-19 in high-risk patients in a Phase 3 clinical trial.
drug development, microbiology, clinical trials
Fecal Microbiota Transplantation Is Poised for a Makeover
Shawna Williams | Jun 1, 2021 | 9 min read
With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.
Week in Review, July 15–19
Jef Akst | Jul 19, 2013 | 5 min read
Bias in preclinical research; medical marijuana for kids; a swath of microbial genomes; plastic ocean habitats; rethinking scientific evaluation
Virus Versus Bacteria
Edyta Zielinska | Apr 17, 2013 | 1 min read
A newly developed drug, modeled after a bacteria-infecting virus, is less likely to become antibiotic resistant.
Clinical Trial Misfortune
Cristina Luiggi | Aug 28, 2012 | 1 min read
A human trial of a hepatitis C treatment is shut down after one of the participants died.